Royal Bank of Canada’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-301,185
| Closed | -$5.42M | – | 7258 |
|
|
2020
Q2 | $5.42M | Buy |
301,185
+78,803
| +35% | +$1.1M | ﹤0.01% | 1889 |
|
|
2020
Q1 | $1.59M | Buy |
222,382
+92,022
| +71% | +$1.15M | ﹤0.01% | 2672 |
|
|
2019
Q4 | $3.11M | Buy |
130,360
+22,096
| +20% | +$610K | ﹤0.01% | 2499 |
|
|
2019
Q3 | $2.9M | Buy |
108,264
+18,308
| +20% | +$514K | ﹤0.01% | 2455 |
|
|
2019
Q2 | $2.44M | Sell |
89,956
-45
| -0% | -$1.41K | ﹤0.01% | 2598 |
|
|
2019
Q1 | $3.12M | Buy |
90,001
+43,670
| +94% | +$1.26M | ﹤0.01% | 2364 |
|
|
2018
Q4 | $904K | Buy |
46,331
+36,583
| +375% | +$752K | ﹤0.01% | 3246 |
|
|
2018
Q3 | $259K | Sell |
9,748
-2,663
| -21% | -$86.9K | ﹤0.01% | 4342 |
|
|
2018
Q2 | $469K | Buy |
12,411
+3,457
| +39% | +$132K | ﹤0.01% | 3830 |
|
|
2018
Q1 | $292K | Sell |
8,954
-89,832
| -91% | -$3.94M | ﹤0.01% | 4076 |
|
|
2017
Q4 | $4.81M | Buy |
98,786
+87,445
| +771% | +$4.42M | ﹤0.01% | 2087 |
|
|
2017
Q3 | $612K | Buy |
11,341
+5,191
| +84% | +$305K | ﹤0.01% | 3640 |
|
|
2017
Q2 | $346K | Sell |
6,150
-389
| -6% | -$15.6K | ﹤0.01% | 3963 |
|
|
2017
Q1 | $256K | Buy |
6,539
+828
| +14% | +$26.4K | ﹤0.01% | 4172 |
|
|
2016
Q4 | $128K | Sell |
5,711
-6,139
| -52% | -$120K | ﹤0.01% | 4748 |
|
|
2016
Q3 | $269K | Buy |
11,850
+700
| +6% | +$16.4K | ﹤0.01% | 4221 |
|
|
2016
Q2 | $263K | Sell |
11,150
-374
| -3% | -$9.23K | ﹤0.01% | 4214 |
|
|
2016
Q1 | $234K | Sell |
11,524
-10,024
| -47% | -$318K | ﹤0.01% | 4262 |
|
|
2015
Q4 | $1.11M | Buy |
21,548
+8,626
| +67% | +$418K | ﹤0.01% | 3029 |
|
|
2015
Q3 | $550K | Sell |
12,922
-1,152
| -8% | -$55.6K | ﹤0.01% | 3405 |
|
|
2015
Q2 | $640K | Buy |
14,074
+12,550
| +823% | +$505K | ﹤0.01% | 3362 |
|
|
2015
Q1 | $58K | Buy |
1,524
+1,250
| +456% | +$42.9K | ﹤0.01% | 4903 |
|
|
2014
Q4 | $8K | Buy |
274
+120
| +78% | +$3.34K | ﹤0.01% | 5686 |
|
|
2014
Q3 | $4K | Buy |
+154
| New | +$4.06K | ﹤0.01% | 5702 |
|
|
2014
Q1 | – | Sell |
-1,000
| Closed | -$26K | – | 6243 |
|
|
2013
Q4 | $26K | Sell |
1,000
-350
| -26% | -$8.51K | ﹤0.01% | 5148 |
|
|
2013
Q3 | $36K | Buy |
+1,350
| New | +$32.1K | ﹤0.01% | 4949 |
|
Royal Bank of Canada's PTLA Position: Q3 2020 in Review
Royal Bank of Canada sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 301,185 shares — an estimated $5.42M sold.
Royal Bank of Canada first reported a position in PTLA in Q3 2013 and held it in 26 quarters. The position peaked at $5.42M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Royal Bank of Canada reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Royal Bank of Canada sold 301,185 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $5.42M.
- Royal Bank of Canada first reported a position in Portola Pharmaceuticals, Inc. in Q3 2013 and held it in 26 quarters.
- Royal Bank of Canada's Portola Pharmaceuticals, Inc. position peaked at $5.42M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Royal Bank of Canada's 13F filing for Q3 2020, filed 16 Nov 2020.